Parallel Advisors’s GW Pharmaceuticals Plc American Depositary Shares GWPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-7
Closed -$2K 3174
2021
Q1
$2K Hold
7
﹤0.01% 2563
2020
Q4
$1K Sell
7
-23
-77% -$2.58K ﹤0.01% 2540
2020
Q3
$3K Hold
30
﹤0.01% 2244
2020
Q2
$3K Hold
30
﹤0.01% 2147
2020
Q1
$2K Sell
30
-37
-55% -$3.92K ﹤0.01% 2210
2019
Q4
$7K Hold
67
﹤0.01% 1886
2019
Q3
$8K Buy
67
+23
+52% +$3.49K ﹤0.01% 1781
2019
Q2
$8K Sell
44
-5
-10% -$865 ﹤0.01% 1690
2019
Q1
$8K Buy
49
+17
+53% +$2.53K ﹤0.01% 1642
2018
Q4
$3K Sell
32
-64
-67% -$8.4K ﹤0.01% 1812
2018
Q3
$17K Buy
96
+35
+57% +$5.05K ﹤0.01% 1230
2018
Q2
$8K Buy
61
+30
+97% +$4.26K ﹤0.01% 1449
2018
Q1
$3K Hold
31
﹤0.01% 1779
2017
Q4
$4K Sell
31
-54
-64% -$6.34K ﹤0.01% 1695
2017
Q3
$10K Sell
85
-9
-10% -$964 ﹤0.01% 1308
2017
Q2
$11K Buy
94
+24
+34% +$2.58K ﹤0.01% 1296
2017
Q1
$8K Hold
70
﹤0.01% 1335
2016
Q4
$8K Buy
+70
New +$8.43K ﹤0.01% 1216

Other funds holding GWPH

Parallel Advisors's GWPH Position: Q2 2021 in Review

Parallel Advisors sold out of GW Pharmaceuticals Plc American Depositary Shares (GWPH) in Q2 2021, closing a stake of 7 shares — an estimated $2K sold.

Parallel Advisors first reported a position in GWPH in Q4 2016 and held it in 18 quarters. The position peaked at $17K in Q3 2018. 1 fund tracked by Wall St. Rank holds GWPH as of Q2 2021.

  • Parallel Advisors reported no remaining GW Pharmaceuticals Plc American Depositary Shares position as of Q2 2021 after selling out during the quarter.
  • Parallel Advisors sold 7 GW Pharmaceuticals Plc American Depositary Shares shares in Q2 2021, an estimated $2K.
  • Parallel Advisors first reported a position in GW Pharmaceuticals Plc American Depositary Shares in Q4 2016 and held it in 18 quarters.
  • Parallel Advisors's GW Pharmaceuticals Plc American Depositary Shares position peaked at $17K in Q3 2018.
  • 1 fund tracked by Wall St. Rank held GW Pharmaceuticals Plc American Depositary Shares as of Q2 2021.

Based on Parallel Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.